Skip to main content

Advertisement

SpringerLink
Log in

Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: Just a coincidence?

  • Review Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Non-alcoholic fatty liver disease (NAFLD) is estimated to afflict ∼20–30% of the general population, and over 70% of the patients with Type 2 diabetes. Given the expected rise in the prevalence of obesity and diabetes, NAFLD will be, if not already there, an epidemic. The consequences of NAFLD are numerous, and range from progression to chronic liver disease with its associated morbidity and mortality, to worsening insulin resistance and Type 2 diabetes, to being a contributor to both cardiovascular disease (CVD) and chronic kidney disease (CKD). NAFLD is, therefore, a complex problem with implications far beyond the liver. This review focuses on the rapidly expanding body of clinical evidence suggesting that NAFLD is associated with an increased prevalence and incidence of both CVD and CKD in patients with diabetes. This association appears to be independent of obesity, hypertension, and other potential confounding factors. However, given the heterogeneity and small number of observational studies, further research is urgently required to corroborate the prognostic role of NAFLD in the development and progression of CVD and CKD among patients with diabetes, and to further elucidate the complex and intertwined mechanisms that link NAFLD with these adverse outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007, 17: 863–9.

    Article  PubMed  Google Scholar 

  2. de Alwis NM, Day CP. Nonalcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008, 48(Suppl 1): S104–12.

    Article  PubMed  Google Scholar 

  3. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab 2008, 93(Suppl 1): S74–80.

    Article  PubMed  Google Scholar 

  4. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28: 27–38.

    Article  PubMed  Google Scholar 

  5. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in nonalcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008, 51: 1947–53.

    Article  PubMed  Google Scholar 

  6. Loria P, Lonardo A, Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond) 2008, 115: 1–12.

    Article  Google Scholar 

  7. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363: 1341–50.

    Article  PubMed  Google Scholar 

  8. Treeprasertsuk S, Lopez-Jimenez F, Lindor KD. Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci 2011, 56: 35–45.

    Article  PubMed  Google Scholar 

  9. Targher G. Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incidenttype 2 diabetes, cardiovascular events, chronic kidney disease and cancer — a narrative review. Clin Chem Lab Med 2010, 48: 147–57.

    Article  PubMed  Google Scholar 

  10. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol 2010, Nov 17 [Epub ahead of print]; doi:10.1016/j.jhep.2010.11.007.

  11. Schindhelm RK, Diamant M, Bakker SJ, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest 2005, 35: 369–74.

    Article  PubMed  Google Scholar 

  12. Targher G, Bertolini L, Padovani R, et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest 2006, 29: 55–60.

    PubMed  Google Scholar 

  13. Petit JM, Guiu B, Terriat B, et al. Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J Clin Endocrinol Metab 2009, 94: 4103–6.

    Article  PubMed  Google Scholar 

  14. McKimmie RL, Daniel KR, Carr JJ, et al. Hepatic steatosis and sub-clinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 2008, 103: 3029–35.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008, 49: 600–7.

    Article  PubMed  Google Scholar 

  16. Lautamäki R, Borra R, Iozzo P, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006, 291: E282–90.

    Article  PubMed  Google Scholar 

  17. Rijzewijk LJ, Jonker JT, van der Meer RW, et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 2010, 56: 225–33.

    Article  PubMed  Google Scholar 

  18. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30: 1212–8.

    Article  PubMed  Google Scholar 

  19. Lu H, Zeng L, Liang B, Shu X, Xie D. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res 2009, 40: 571–5.

    Article  PubMed  Google Scholar 

  20. Targher G, Bertolini L, Padovani R, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010, 53: 713–8.

    Article  PubMed  Google Scholar 

  21. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010, 105: 1567–73.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54: 3541–6.

    Article  PubMed  Google Scholar 

  23. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30: 2119–21.

    Article  PubMed  Google Scholar 

  24. Hwang ST, Cho YK, Yun JW, et al. Impact of NAFLD on microalbuminuria in patients with prediabetes and diabetes. Intern Med J 2010, 40: 437–42.

    Article  PubMed  Google Scholar 

  25. Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008, 51: 444–50.

    Article  PubMed  Google Scholar 

  26. Targher G, Bertolini L, Chonchol M, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 2010, 53: 1341–8.

    Article  PubMed  Google Scholar 

  27. Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyltransferase concentrations and chronic kidney disease in the United States population. Findings from the National Health and Nutrition Examination Survey 2001–2006. Nutr Metab Cardiovasc Dis 2010, 20: 583–90.

    Article  PubMed  Google Scholar 

  28. Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008, 19: 1564–70.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010, 21: 406–12.

    Article  PubMed  Google Scholar 

  30. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009, 35: 277–87.

    Article  PubMed  Google Scholar 

  31. Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev 2009, 10: 412–9.

    Article  PubMed  Google Scholar 

  32. Tilg H, Moschen AR. Insulin resistance, inflammation, and nonalcoholic fatty liver disease. Trends Endocrinol Metab 2008, 19: 371–9.

    Article  PubMed  Google Scholar 

  33. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a communitybased population. JAMA 2004, 291: 844–50.

    Article  PubMed  Google Scholar 

  34. Vlagopoulos PT, Sarnak MJ. Traditional and non-traditional cardiovascular risk factors in chronic kidney disease. Med Clin North Am 2005, 89: 587–611.

    Article  PubMed  Google Scholar 

  35. Kendrick J, Chonchol MB. Non-traditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008, 4: 672–81.

    Article  PubMed  Google Scholar 

  36. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009, 5: 677–89.

    Article  PubMed  Google Scholar 

  37. Zoppini G, Targher G, Trombetta M, Lippi G, Muggeo M. Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. Obesity (Silver Spring) 2009, 17: 370–4.

    Article  Google Scholar 

  38. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009, 106: 15430–5.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010, 51: 1979–87.

    Article  PubMed Central  PubMed  Google Scholar 

  40. D’Adamo E, Cali AM, Weiss R, et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care 2010; 33: 1817–22.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Targher G, Bellis A, Fornengo P, et al. Prevention and treatment of nonalcoholic fatty liver disease. Dig Liver Dis 2010, 42: 331–40.

    Article  PubMed  Google Scholar 

  42. Harrison SA, Day CP. Benefits of lifestyle modifications in NAFLD. Gut 2007, 56: 1760–9.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008, 134: 1682–98.

    Article  PubMed  Google Scholar 

  44. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008, 48: 662–9.

    Article  PubMed  Google Scholar 

  45. Sanyal AJ, Chalasani N, Kowdley KV, et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362: 1675–85.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Endocrinology and Metabolism, Department of Medicine, University of Verona, Ospedale Civile Maggiore, Piazzale A. Stefani 1, 37126, Verona, Italy

    G. Targher MD, I. Pichiri & G. Zoppini

  2. Division of Renal Diseases and Hypertension, University of Colorado, Aurora, CO, USA

    M. Chonchol

Authors
  1. G. Targher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Chonchol
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Pichiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Zoppini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Targher MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Targher, G., Chonchol, M., Pichiri, I. et al. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: Just a coincidence?. J Endocrinol Invest 34, 544–551 (2011). https://doi.org/10.3275/7614

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/7614

Key-words

Search

Navigation